HEXABRIX Drug Patent Profile

Which patents cover Hexabrix, and what generic alternatives are available?

Hexabrix is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in HEXABRIX is ioxaglate meglumine; ioxaglate sodium. Additional details are available on the ioxaglate meglumine; ioxaglate sodium profile page.

Summary for HEXABRIX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	373
DailyMed Link:	HEXABRIX at DailyMed

Recent Clinical Trials for HEXABRIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guerbet	Phase 4
NYU Langone Health	Phase 4
New York University School of Medicine	Phase 4

See all HEXABRIX clinical trials

US Patents and Regulatory Information for HEXABRIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Guerbet	HEXABRIX	ioxaglate meglumine; ioxaglate sodium	INJECTABLE;INJECTION	018905-002	Jul 26, 1985		DISCN	No	No

Expired US Patents for HEXABRIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Guerbet	HEXABRIX	ioxaglate meglumine; ioxaglate sodium	INJECTABLE;INJECTION	018905-002	Jul 26, 1985	4,014,986
Guerbet	HEXABRIX	ioxaglate meglumine; ioxaglate sodium	INJECTABLE;INJECTION	018905-002	Jul 26, 1985	4,065,553
Guerbet	HEXABRIX	ioxaglate meglumine; ioxaglate sodium	INJECTABLE;INJECTION	018905-002	Jul 26, 1985	4,094,966
Guerbet	HEXABRIX	ioxaglate meglumine; ioxaglate sodium	INJECTABLE;INJECTION	018905-002	Jul 26, 1985	4,065,554

International Patents for HEXABRIX

See the table below for patents covering HEXABRIX around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1488903
Netherlands	7506400
Israel	47297	DERIVATIVES OF BENZOIC ACID,THEIR PREPARATION AND X-RAY CONTRAST MEDIA CONTAINING THEM
Czechoslovakia	207562	METHOD OF MAKING THE DERIVATIVES OF ACIDS OF 2,4,6-TRIIOD-3/OR 5/-/2,4,6-TROIOD-3/OR 5/-AMINOBENZOYL/-AMINOALCANOYL-AMIDOBENZOO
Finland	821405
Spain	437996

Market Dynamics and Financial Trajectory for HEXABRIX: A Comprehensive Analysis

Last updated: December 31, 2025

Executive Summary

HEXABRIX (generic name: hexaminolevulinate), marketed by IPN Medical Holdings and Photocure, is an image-guided fluorescence diagnostic agent primarily used in photodynamic diagnosis (PDD) during bladder cancer surgeries. Since its FDA approval in 2016 and European CE marking, HEXABRIX has experienced steady growth driven by increasing adoption of fluorescence cystoscopy, supportive clinical data, and expanding geographic access. This report analyzes current market dynamics, competitive landscape, revenue projections, challenges, and opportunities shaping HEXABRIX’s future trajectory.

---

Introduction

HEXABRIX is a proprietary, optically activated agent utilized to visualize bladder tumors more accurately during transurethral resection (TURBT). It enhances the detection of carcinoma in situ (CIS) and other neoplastic tissue, thereby improving surgical outcomes. Its success hinges on the surge in minimally invasive urologic procedures and the shift toward more precise diagnostic tools.

---

1. Market Overview

1.1. Indication and Clinical Usage

Application Area	Primary Use	Key Benefits	Regulatory Status
Bladder Cancer Detection	Fluorescent imaging during cystoscopy	Enhanced tumor visibility, reduced recurrence	FDA (2016), CE (2015)

1.2. Market Size and Growth Trends

Region	2022 Market Size (USD millions)	Compound Annual Growth Rate (CAGR, 2022-2027)	Growth Drivers
North America	210	8.2%	Rising bladder cancer incidence, adoption of fluorescence cystoscopy
Europe	150	7.5%	Healthcare policies favoring minimally invasive diagnostics
Asia-Pacific	60	12.0%	Growing healthcare infrastructure, increasing cancer screening
Rest of World	30	9.0%	Urbanization, increased healthcare spending

Total Market (2022): approx. USD 450 million; Projected 2027: USD 650-700 million.

1.3. Key Factors Influencing Growth

• Rising Prevalence of Bladder Cancer: According to American Cancer Society, over 83,000 new cases of bladder cancer are diagnosed annually in the U.S., with a significant proportion suitable for fluorescence-guided surgery.
• Shift Toward Precision Surgery: Growing emphasis on complete tumor resection reduces recurrence and progression risks.
• Regulatory Approvals: Expanded indications and approvals, especially in emerging markets.
• Reimbursement Landscape: Increasing insurance coverage for fluorescence-guided cystoscopy in developed markets.

---

2. Competitive Landscape

2.1. Major Players and Alternatives

Competitor	Product Name	Market Share (Estimated, 2022)	Key Advantages
Photocure	HEXABRIX	65%	Proven efficacy, established presence
Oncurious (FDA)	Hexaminolevulinate (Uriglumast)	5%	Emerging product, pending approval in some regions
Imaging Technologies	Fluorescence Dyes	20%	Variations of fluorescing agents, lower cost
Others	Various Biosciences	10%	Regional products, off-label uses

2.2. Market Competition Factors

• Efficacy and Diagnostic Accuracy: HEXABRIX has demonstrated higher tumor detection rates (up to 25% increase compared to white light cystoscopy).
• Regulatory Status: Approval timelines and indications.
• Pricing Strategy: Cost of agents and reimbursement policies.
• Adoption Rate: Training, clinical familiarity, and healthcare infrastructure.

---

3. Financial Trajectory and Revenue Forecasts

3.1. Revenue Drivers

Driver	Impact	Data/Assumption
Market Penetration	Increased usage in urology centers	10-15% annual growth in established markets
Geographic Expansion	Entry into Asia and Latin America	20-25% growth rate post-entry
Clinical Evidence	New studies supporting benefits	Adoption driven by positive outcomes
Regulatory Approvals	Broader indications	Heightened usage and procurement

3.2. Revenue Projection Model (2023-2027)

Year	Estimated Revenue (USD millions)	CAGR	Key Milestones
2023	180	—	Stabilized growth, increased adoption
2024	220	22%	Regional expansion, new clinical data
2025	270	23%	New indications, reimbursement gains
2026	330	22%	Market maturation, greater hospital integration
2027	400	21%	Potential entry into new markets or devices integration

Note: This projection assumes continued regulatory support, stable pricing, and rapid expansion in less mature markets.

---

4. Regulatory and Policy Dynamics

4.1. Regulatory Milestones

• FDA Approval (2016): Pivotal for North American sales.
• European CE Mark (2015): Catalyzed adoption across the EU.
• Emerging Markets: Regulatory pathways vary; approvals are pending in countries like China, India, and Brazil.

4.2. Reimbursement Policies

• In the U.S., reimbursement codes for fluorescence cystoscopy (CPT codes 52234, 52234-52) facilitate provider adoption.
• European nations increasingly include such agents in bundled reimbursements.

4.3. Policy Challenges

• Off-label competition.
• Conservative adoption due to unfamiliarity or cost considerations.
• Variability in healthcare infrastructure.

---

5. Key Challenges and Opportunities

5.1. Challenges

Issue	Impact	Mitigation Strategies
High Cost	Limits adoption in cost-sensitive markets	Price optimization, demonstrating cost-effectiveness
Competition from Alternatives	Market share erosion	Emphasize superior clinical data
Regulatory Delays	Market access bottlenecks	Engage early with authorities
Off-Label Use	Safety and efficacy concerns	Invest in clinical trials

5.2. Opportunities

Area	Strategic Focus	Expected Outcomes
Geographic Expansion	Target emerging markets	Accelerated revenue growth
Product Innovation	Combining HEXABRIX with device tech	Enhanced diagnostic accuracy
Clinical Evidence Development	Large-scale studies	Increased clinician confidence
Partnerships	Collaborations with device manufacturers	Broader market penetration

---

6. Comparative Analysis with Alternative Diagnostics

Parameter	HEXABRIX	White Light Cystoscopy	Other Fluorescent Agents
Detection Rate Increase	Up to 25%	Baseline	Varies
Reimbursement Coverage	Growing	Standard	Limited
Ease of Use	High	Standard	Varies
Cost	Premium	Lower	Similar
Clinical Evidence	Robust	Moderate	Emerging

7. Future Outlook

The outlook for HEXABRIX remains optimistic given technological enhancements, regulatory momentum, and increasing acceptance of fluorescence-guided diagnostics. The key to maximizing growth lies in expanding geographic presence, integrating with advanced imaging platforms, and solidifying clinical evidence.

---

Key Takeaways

• Market Expansion Is Critical: Continued globalization and regulatory approvals in emerging markets are essential to sustain long-term growth.
• Clinical Evidence Drives Adoption: Demonstrated improvements in detection rates and patient outcomes bolster clinician confidence and reimbursement.
• Competitive Positioning Matters: Maintaining technological superiority and strategic pricing will distinguish HEXABRIX amidst emerging alternatives.
• Reimbursement and Policy Support Are Vital: Navigating diverse healthcare policies influences revenue trajectory.
• Innovation Is a Growth Catalyst: Integration with imaging devices and development of next-generation agents can open new markets.

---

FAQs

Q1: What factors most influence HEXABRIX's market penetration?
A: Clinical efficacy, regulatory approvals, reimbursement support, and clinician familiarity.

Q2: How does HEXABRIX compare cost-wise with alternative diagnostic agents?
A: HEXABRIX generally commands a premium due to superior clinical data, but cost-effectiveness is also driven by reduced recurrence rates and improved outcomes.

Q3: Which regions present the greatest growth opportunities for HEXABRIX?
A: Asia-Pacific, Latin America, and Eastern Europe, due to rising healthcare infrastructure and increased bladder cancer incidence.

Q4: What are primary challenges hindering HEXABRIX’s expansion?
A: High costs, regulatory delays, competition from lower-cost alternatives, and variation in reimbursement policies.

Q5: What strategies could enhance HEXABRIX’s future financial performance?
A: Expanding clinical evidence, entering new markets, innovative product integration, and partnerships with device manufacturers.

---

References

[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] Photocure. (2022). HEXABRIX Product Information.
[3] U.S. Food and Drug Administration. (2016). FDA approval summary for HEXABRIX.
[4] European Medicines Agency. (2015). CE marking documentation for HEXABRIX.
[5] MarketWatch. (2023). Global Fluorescence-guided Diagnostics Market Report.
[6] IQVIA. (2022). Urology Device and Diagnostic Market Data.

---

This analysis is intended for informational purposes and should inform strategic planning, investment considerations, and market entry strategies related to HEXABRIX.